Charles Schwab Investment Management Inc. Purchases 13,942 Shares of Neurocrine Biosciences, Inc. $NBIX

Charles Schwab Investment Management Inc. grew its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 789,715 shares of the company’s stock after purchasing an additional 13,942 shares during the period. Charles Schwab Investment Management Inc. owned about 0.80% of Neurocrine Biosciences worth $99,259,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of NBIX. IFP Advisors Inc raised its holdings in shares of Neurocrine Biosciences by 4.2% during the 2nd quarter. IFP Advisors Inc now owns 2,172 shares of the company’s stock valued at $273,000 after buying an additional 88 shares in the last quarter. Linden Thomas Advisory Services LLC grew its position in Neurocrine Biosciences by 1.5% during the second quarter. Linden Thomas Advisory Services LLC now owns 6,699 shares of the company’s stock valued at $842,000 after acquiring an additional 96 shares during the last quarter. Central Pacific Bank Trust Division raised its stake in shares of Neurocrine Biosciences by 6.2% during the second quarter. Central Pacific Bank Trust Division now owns 1,725 shares of the company’s stock worth $217,000 after acquiring an additional 100 shares in the last quarter. AdvisorShares Investments LLC raised its stake in shares of Neurocrine Biosciences by 2.8% during the second quarter. AdvisorShares Investments LLC now owns 3,666 shares of the company’s stock worth $461,000 after acquiring an additional 100 shares in the last quarter. Finally, Nissay Asset Management Corp Japan ADV lifted its holdings in shares of Neurocrine Biosciences by 0.9% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 12,293 shares of the company’s stock worth $1,360,000 after acquiring an additional 107 shares during the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In related news, CEO Kyle Gano sold 300 shares of the business’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $141.97, for a total transaction of $42,591.00. Following the transaction, the chief executive officer owned 140,407 shares in the company, valued at $19,933,581.79. The trade was a 0.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director George J. Morrow sold 15,000 shares of the stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $143.37, for a total transaction of $2,150,550.00. Following the completion of the transaction, the director directly owned 7,068 shares of the company’s stock, valued at approximately $1,013,339.16. The trade was a 67.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 33,300 shares of company stock valued at $4,925,901. 4.80% of the stock is currently owned by company insiders.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $152.00 on Friday. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $157.67. The stock has a market capitalization of $15.16 billion, a PE ratio of 36.36, a PEG ratio of 0.94 and a beta of 0.22. The business’s 50-day moving average is $142.87 and its 200 day moving average is $134.81.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.59. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The firm had revenue of $794.90 million for the quarter, compared to analysts’ expectations of $746.61 million. During the same period in the previous year, the firm earned $1.81 earnings per share. The business’s revenue was up 27.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on NBIX shares. Truist Financial reaffirmed a “buy” rating and set a $172.00 target price (up previously from $165.00) on shares of Neurocrine Biosciences in a report on Thursday, October 30th. Zacks Research raised Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 15th. Wedbush reiterated an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, September 22nd. Citigroup increased their target price on Neurocrine Biosciences from $175.00 to $203.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, Royal Bank Of Canada raised their price target on Neurocrine Biosciences from $156.00 to $160.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average price target of $170.53.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.